Supplier (asset manager) profile of Concarlo Holdings LLC
CONCARLO Holdings, LLC is a precision medicine oncology company, whose goal is to develop novel inhibitors and diagnostics to extend the lives of metastatic breast cancer patients. Concarlo’s business development efforts during its first four years included the successful acquisition of a competitive NIH SBIR Phase 1grant and a contract from the NIH Nanoparticle Characterization Lab, financing from the NY SEED fund, the Cavendish Impact Foundation, and University of Buffalo Economic Development Corporation. We have raised $4.5M from FF rounds, and will open our convertible bond pre-Series A round in September 2021. We estimate $15M will be required to take IpY to the Clinic. With this raise, we intend to begin our FIH trial in 2 years. Our lead IpY is a $2B+ opportunity to treat drug-resistant Breast Cancer by targeting p27Kip1.
Per asset class:
Private capital
$5m – $25m
Access to offered investments
You are viewing the profile currently as non-logged in user. If you already have an account please log in or register for a free account to see the investments.Alternatively, you can continue without login by indicating your:
About SmartMoneyMatch
Pages
Stay connected
Subscribe to our monthly newsletter
